FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2009597130> ?p ?o ?g. }

• W2009597130 endingPage "376" @default.
• W2009597130 startingPage "375" @default.
• W2009597130 abstract "We read in HEPATOLOGY a very interesting and valuable article1 suggesting that the simultaneous targeting of epidermal growth factor receptor (ErbB1) and human epidermal growth factor receptor 2 (ErbB2) could potentially be a selective strategy for cholangiocarcinoma therapy. Reading this article and considering our own study on the treatment of cholangiocarcinoma with a combinative strategy involving tamoxifen and other chemotherapeutic drugs, we see indications that the use of tamoxifen for cholangiocarcinoma prevention and treatment will become more popular. Tamoxifen is a classic drug for estrogen receptor–positive primary breast cancer that is positive for ErbB1 and/or ErbB2,2 and the same mechanism could be indicated for the treatment of cholangiocarcinoma. We have also performed some experiments with this strategy (as mentioned later), and now we think that the expression levels of ErbB1, ErbB2, or both could be markers for the effects of tamoxifen. To find new ways of using chemotherapeutics for human cholangiocarcinoma, we have been paying attention to the growth-inhibition effects of tamoxifen in combination chemotherapeutics. Some of our pilot studies have shown that tamoxifen can lead to increased cell damage by competing with other chemotherapeutic molecules for binding sites on P-glycoprotein and by limiting the extracellular transport of drugs from the human cholangiocarcinoma cell line QBC939.3, 4 Because cholangiocarcinoma cells gradually develop resistance to conventional chemotherapeutic drugs, we have selected tamoxifen as a sensitizer that competes with chemotherapeutic drugs as the P-glycoprotein substrate for the P-glycoprotein binding site and enhances the drug concentration and effects of chemotherapy.3 To further our study, we have established a human, multidrug-resistant cholangiocarcinoma cell line (QBC939/ADM).4 We are now investigating the specific signal transduction pathway by which tamoxifen decreases P-glycoprotein expression levels, and we are determining whether other mechanisms are involved. Furthermore, tamoxifen has been used primarily to treat patients with nonbreast cancers, including hepatocellular, pancreatic, renal cell, ovarian, and melanoma carcinomas.3 Above all, we believe that although the use of tamoxifen for the prevention of breast cancer is exceptionally low, the use of tamoxifen for cancer prevention and treatment will become more popular and extensive with the decision-making process. Zhihua Liu Ph.D.*, Yanlei Ma Ph.D.*, Huanlong Qin M.D.*, * Department of Surgery, Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic of China." @default.
• W2009597130 created "2016-06-24" @default.
• W2009597130 creator A5022411400 @default.
• W2009597130 creator A5055765857 @default.
• W2009597130 creator A5075258838 @default.
• W2009597130 date "2010-11-03" @default.
• W2009597130 modified "2023-10-16" @default.
• W2009597130 title "Combinative strategy using tamoxifen and other chemotherapeutic drugs for cholangiocarcinoma chemotherapy" @default.
• W2009597130 cites W2040338950 @default.
• W2009597130 cites W2072462492 @default.
• W2009597130 cites W2072583045 @default.
• W2009597130 cites W2114167623 @default.
• W2009597130 doi "https://doi.org/10.1002/hep.23900" @default.
• W2009597130 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21254190" @default.
• W2009597130 hasPublicationYear "2010" @default.
• W2009597130 type Work @default.
• W2009597130 sameAs 2009597130 @default.
• W2009597130 citedByCount "2" @default.
• W2009597130 countsByYear W20095971302018 @default.
• W2009597130 crossrefType "journal-article" @default.
• W2009597130 hasAuthorship W2009597130A5022411400 @default.
• W2009597130 hasAuthorship W2009597130A5055765857 @default.
• W2009597130 hasAuthorship W2009597130A5075258838 @default.
• W2009597130 hasConcept C121608353 @default.
• W2009597130 hasConcept C126322002 @default.
• W2009597130 hasConcept C143998085 @default.
• W2009597130 hasConcept C2776067312 @default.
• W2009597130 hasConcept C2776694085 @default.
• W2009597130 hasConcept C2777176818 @default.
• W2009597130 hasConcept C2779438470 @default.
• W2009597130 hasConcept C502942594 @default.
• W2009597130 hasConcept C530470458 @default.
• W2009597130 hasConcept C71924100 @default.
• W2009597130 hasConcept C98274493 @default.
• W2009597130 hasConceptScore W2009597130C121608353 @default.
• W2009597130 hasConceptScore W2009597130C126322002 @default.
• W2009597130 hasConceptScore W2009597130C143998085 @default.
• W2009597130 hasConceptScore W2009597130C2776067312 @default.
• W2009597130 hasConceptScore W2009597130C2776694085 @default.
• W2009597130 hasConceptScore W2009597130C2777176818 @default.
• W2009597130 hasConceptScore W2009597130C2779438470 @default.
• W2009597130 hasConceptScore W2009597130C502942594 @default.
• W2009597130 hasConceptScore W2009597130C530470458 @default.
• W2009597130 hasConceptScore W2009597130C71924100 @default.
• W2009597130 hasConceptScore W2009597130C98274493 @default.
• W2009597130 hasIssue "1" @default.
• W2009597130 hasLocation W20095971301 @default.
• W2009597130 hasLocation W20095971302 @default.
• W2009597130 hasOpenAccess W2009597130 @default.
• W2009597130 hasPrimaryLocation W20095971301 @default.
• W2009597130 hasRelatedWork W110384481 @default.
• W2009597130 hasRelatedWork W1514995717 @default.
• W2009597130 hasRelatedWork W1771722205 @default.
• W2009597130 hasRelatedWork W188673006 @default.
• W2009597130 hasRelatedWork W2009869235 @default.
• W2009597130 hasRelatedWork W2091599823 @default.
• W2009597130 hasRelatedWork W2124861559 @default.
• W2009597130 hasRelatedWork W2401100240 @default.
• W2009597130 hasRelatedWork W2460391067 @default.
• W2009597130 hasRelatedWork W2181705735 @default.
• W2009597130 hasVolume "53" @default.
• W2009597130 isParatext "false" @default.
• W2009597130 isRetracted "false" @default.
• W2009597130 magId "2009597130" @default.
• W2009597130 workType "article" @default.